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Highlights 
 The risk of persistent disease after normal hCG is extremely low for a partial mole 
 For a partial mole, one serum hCG at a month after hCG normalisation is now advised 
 The risk of persistent disease after normal hCG is higher for a complete mole (CHM) 
 First normal hCG after 56 days increases persistent disease risk 3.8-fold for a CHM 
 The current hCG surveillance protocol following a CHM remains unchanged 
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ABSTRACT 
OBJECTIVE: To quantify the risk of developing post-molar gestational trophoblastic neoplasia (pGTN) 
beyond the first normal Human Chorionic Gonadotrophin (hCG) in women who have had a complete 
(CHM) or partial molar pregnancy (PHM) and to re-evaluate the current UK Hydatidiform mole hCG 
surveillance guidelines. 
METHODS: The Charing Cross Hospital Trophoblast Disease Centre database was screened to identify 
all registered cases of hydatidiform mole (HM) between 1980 and 2009.  
RESULTS: We identified 20,144 cases of HM, comprising 8,400 CHM, 9,586 PHM, and 2,158 cases of 
unclassified hydatidiform mole (UHM). Twenty-nine cases (20 CHM, 3 PHM and 6 UHM) developed 
pGTN after the first normal hCG. For CHM the risk of pGTN at the point of hCG normalisation was 1 in 
406, and fell rapidly in the first six months of monitoring. For PHM the risk of pGTN at the point of hCG 
normalisation was 1 in 3,195. Women with CHM where hCG normalisation occurred beyond 56 days 
after uterine evacuation of molar tissue were found to have a 3.8-fold higher risk of pGTN.     
CONCLUSIONS: Our results show that pGTN can occur after hCG normalisation following PHM but the 
risk is extremely low. Women with CHM have a comparatively higher risk of pGTN after hCG 
normalisation. Those with CHM where hCG normalises within 56 days represent a group with a lower 
risk of pGTN. We have revised the current UK hCG surveillance protocol for PHM to a single additional 
confirmatory normal urine hCG measurement one month after first normalisation. The protocol for 
CHM remains unchanged. 
KEYWORDS:  Molar pregnancy, complete hydatidiform mole, partial hydatidiform mole, gestational 
trophoblastic disease, post-molar gestational trophoblastic neoplasia, human chorionic 
gonadotrophin. 
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INTRODUCTION: 
In the UK, Human Chorionic Gonadotrophin (hCG) surveillance is performed on all registered women 
with hydatidiform molar pregnancies (HM) in three regional trophoblastic disease units (London, 
Sheffield and Dundee). The majority fall into two groups; those who develop post-molar gestational 
trophoblastic neoplasia (pGTN) prior to hCG normalisation and require chemotherapy, and those with 
HM that undergo spontaneous resolution without requiring treatment. There is also a third, much 
rarer outcome where HM appears to undergo spontaneous resolution, with normalisation of serum 
hCG, but subsequently relapse and develop pGTN. This risk is much higher for a complete hydatidiform 
mole (CHM) than a partial hydatidiform mole (PHM) (1).  pGTN is potentially life threatening 
malignancy, but has a cure rate in the UK of around 100% (1). This is dependent on early detection of 
relapse and prompt initiation of chemotherapy. Once hCG levels normalise, surveillance continues to 
ensure that any subsequent relapse is detected and treated promptly.  
A key issue is how long this surveillance is required. Following evacuation of a HM, the UK hCG 
surveillance policy has been to measure serum hCG with a centralised assay every two weeks until 
hCG normalisation. Following hCG normalisation urinary hCG is then monitored with a centralised 
assay every four weeks and continues for six months from the date of hCG normalisation. If urinary 
hCG remains within the normal range, surveillance is then discontinued. Where hCG normalisation 
occurs within 56 days the risk of subsequent relapse is thought to be lower. In this sub-group, hCG 
surveillance is shortened to six months from the date of evacuation rather than from hCG 
normalisation. The same protocol applied to cases of both CHM and PHM.  
Previous research has suggested that the risk of developing pGTN after the first normal hCG is zero for 
women with a PHM and very low with a CHM (2). It has been proposed that hCG surveillance can be 
shortened to perhaps just the first normal hCG value, however this is based on data from 
comparatively small case series subject to case ascertainment bias (2). Using a 56 day cut-off to define 
a sub-group at lower risk of pGTN originates from research in a small data set (4,205 women), which 
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found that where hCG fell to normal within 56 days, there were no cases of pGTN (3). Here we have 
re-evaluated the current hCG surveillance protocol (4) in a very large population based cohort and 
present the evidence to support a revised UK hCG surveillance protocol.  
METHODS: 
The electronic database at Charing Cross Hospital was screened to identify all registered cases of HM 
for hCG surveillance between 01st of January 1980 and 31st of December 2009. This period was chosen 
because of the availability of centralised pathological review and to allow time for subsequent cases 
of pGTN to be captured. Cases were excluded where a diagnosis was reclassified as non-molar after 
central pathology review and where chemotherapy was administered prior to hCG normalisation.  
Cases of HM were identified as CHM, PHM and unclassified hydatidiform mole (UHM). The time from 
uterine evacuation of the molar tissue to hCG normalisation was recorded.  These cases were screened 
to identify women who underwent hCG normalisation and subsequently developed pGTN. The 
ongoing risk of pGTN according to the duration of hCG monitoring was also calculated. 
 It is likely that the majority of cases of UHM represent unidentified cases of CHM which were 
diagnosed prior to the availability of p57KIP2 staining. We therefore undertook a combined analysis for 
these cases to determine the rates of pGTN beyond hCG normalisation following CHM. 
The data was examined to determine the risk of being diagnosed with pGTN where hCG fell to normal 
within 56 days to re-evaluate the importance of the 56-day cut off to define high and low risk groups. 
Where no date of hCG normalisation was available it was assumed that this occurred prior to 
registration and therefore within 56 days. Significance testing was undertaking using Fisher’s exact 
test or Pearson’s Chi-square test with Yates correction according to the sample size. This study 
complied with local regulations and was approved by the institutional review boards of Imperial 
College London. Patient details were anonymised and therefore patient consent was not required. 
RESULTS: 
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We identified 20,144 women registered with HM between 1980 and 2009, comprising of 9,586 PHM, 
8,400 CHM and 2,158 UHM. Figure 1 shows the cases identified and the reasons for exclusions. There 
were 29 women who developed pGTN after hCG normalisation. 14 women developed pGTN within, 
and 15 women beyond, the time limits of the current surveillance protocol.  
PHM 
There were three women with PHM that developed pGTN after the first normal hCG. For women with 
PHM the risk of pGTN developing at the point of hCG normalisation was very low at 1 in 3,195. This 
risk of pGTN developing was reduced three-fold after six months to 1 in 9,584. Table 1 summarises 
the risks of pGTN developing from hCG normalisation for PHM. 
CHM 
There were 20 women with CHM that developed pGTN after the first normal hCG. For women with 
CHM the risk of pGTN developing at the point of hCG normalisation was 1 in 420. This risk halved after 
four months to 1 in 839 and halved again after twelve months to 1 in 1,677. Table 2 summarises the 
risks of pGTN developing over the first 12 months from hCG normalisation for CHM. 
UHM 
There were six women with UHM that developed pGTN after the first normal hCG. For women with 
UHM the risk of pGTN developing at the point of hCG normalisation was 1 in 360. This risk halved after 
12 months to 1 in 718. Table 3 summarises the risks of pGTN developing over the first 12 months from 
hCG normalisation for UHM.  
 
 
CHM and UHM combined 
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In view of the similar risks of pGTN seen with UHM and CHM, it seems likely that most UHM were in 
fact CHM. Indeed there was no significant difference between the risk of pGTN developing in women 
with CHM and UHM at the time of hCG normalisation [Odds-ratio (OR) 0.86, 95% confidence interval 
(CI) 0.34-2.13]. When the data for CHM and UHM are combined there were 26 women that developed 
pGTN after the first normal hCG. For women with CHM or UHM the risk of pGTN at the point of hCG 
normalisation was 1 in 406. This risk was reduced at six months to 1 in 753. Table 4 summarises the 
risks of pGTN developing in the first 12 months from hCG normalisation for CHM and UHM combined. 
Risk of pGTN where hCG normalisation occurs within 56 days of uterine evacuation of molar tissue 
Overall, there were 7,479 women with HM where hCG normalisation occurred within 56 days and of 
these, only four women subsequently developed pGTN. There were 12,665 women with HM where 
hCG normalisation occurred after 56 days and of these 25 subsequently developed pGTN. Table 5 
summarises the risks of developing pGTN for each subtype of HM according to whether hCG 
normalisation occurred within or after 56 days. No significant difference in the risk of pGTN in cases 
of PHM undergoing hCG normalisation before and after 56 days was detected. For women with CHM 
(or UHM) undergoing hCG normalisation within 56 days had a significantly lower risk of developing 
pGTN than women undergoing hCG normalisation after 56 days (OR 0.27 95% CI 0.08-0.88, p=0.03).  
DISCUSSION: 
Previous research has suggested that the risk of developing pGTN after the first normal hCG is zero for 
women with a PHM (2). Our results are based on a much larger population and show that pGTN can 
occur after hCG normalisation following PHM but the risk is greater than seven fold lower than after 
CHM (or UHM). For PHM, whatever cut off for hCG surveillance is used, the risk of pGTN remains very 
low. Extending surveillance doesn’t necessarily catch all relapses as some can occur very late. We have 
revised the current UK hCG surveillance protocol for PHM to one urine hCG measurement at a month 
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after hCG normalisation. This is to ensure that the first normal value was correct and not a laboratory 
or sample error. 
For women diagnosed with CHM (or UHM), the risk of pGTN after hCG normalisation has been 
confirmed to be small but real and falls rapidly in the first six months of monitoring. In cases of CHM 
(or UHM) where hCG normalisation occurred beyond 56 days, the risk of pGTN was 3.8-fold higher 
than where hCG normalised within 56 days. This provides evidence from a large data-set to support 
the current hCG surveillance protocol following CHM, which remains unchanged.  
This is a large population based study, and therefore not subject to case-ascertainment bias. Other 
strengths include central pathology review and the use of a single well characterised hCG assay. A 
potential limitation of the study is that the classification of UHM is based on morphological rather 
than cytogenetic criteria and therefore, whilst the majority of cases are likely to represent 
unestablished CHM this remains unproven. Furthermore, despite the large number of cases, the actual 
number developing pGTN following a normal hCG is very small so the study might be viewed as 
underpowered.  
The optimal duration of hCG monitoring beyond normalisation should minimise the risk of missed 
relapses but should not cause unnecessary delay to those hoping to try for a child or prolong the 
anxiety associated with monitoring. Future surveys could help to establish the acceptable period of 
hCG surveillance for women with CHM who intend to attempt to have further children. This research 
provides tables describing the estimated risk of pGTN following hCG normalisation for CHM and PHM 
which have not existed previously. These tables could be used to empower patients to choose their 
own duration of surveillance. 
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Figure 1: Women with HM identified between 1980 and 2009 according to subtype, and the timing of 
hCG normalisation (≤56 days, or >56 days after evacuation of uterine molar tissue). 
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Table 1: Calculated risks of pGTN from hCG normalisation for PHM 
Months after 
 hCG normalisation 
Cases in remission 
 (hCG normal) 
Cumulative cases of pGTN  
(total n=3) 
Remaining risk of pGTN 
after this time point 
0 9,586 0 1 in 3,195 
4 9,585 1 1 in 4,793 
6 9,584 2 1 in 9,584 
8 9,583 3 0 
 
Table 2: Calculated risks of pGTN in the first 12 months from hCG normalisation for CHM 
Months after hCG 
normalisation 
Cases in remission 
 (hCG normal) 
Cumulative cases of pGTN  
(total n=20) 
Remaining risk of pGTN 
after this time point 
0 8,400 0 1 in 420 
1 8,395 5 1 in 560 
2 8,391 9 1 in 763 
4 8,390 10 1 in 839 
7 8,389 11 1 in 932 
8 8,388 12 1 in 1,049 
10 8,387 13 1 in 1,189 
12 8,385 15 1 in 1,677 
Table 3: Calculated risks of pGTN in the first 12 months from hCG normalisation for UHM 
Months after hCG 
normalisation 
Cases in Remission 
 (hCG normal) 
Cumulative cases of pGTN  
(total n=6) 
Remaining risk of pGTN 
after this time point 
Assessed for eligibility
(n =22,959) 
Excluded (n = 2,975 )
Reclassified as non- molar abortion
(n =1,212)
Reclassified with other diagnosis 
(n =127)
Received chemotherapy before 
hCG normalisation
(n=1,476) 
 
HM
(n =20,144) 
           PHM
(n =9,586 )
          UHM 
(n =2,158 )
          CHM
(n = 8,400 )
hCG
normal  
≤56 days 
(n=4,002) 
hCG
normal 
>56 days 
(n=5,584) 
hCG 
normal  
≤56 days 
(n=2,719) 
hCG
normal 
>56 days 
(n=5,681) 
hCG
normal  
≤56 days 
(n=758)
hCG
normal 
>56 days 
(n=1,400) 
hCG
normal  
≤56 days 
then PTD 
(n=1)
hCG
normal  
>56 days 
then PTD 
(n=2)
hCG 
normal  
≤56 days 
then PTD 
(n=3)
hCG
normal  
>56 days 
then PTD 
(n=17) 
hCG
normal  
≤56 days 
then PTD 
(n=0)
hCG
normal  
>56 days 
then PTD 
(n=6)
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0 2,158 0 1 in 360 
5 2,157 1 1 in 431 
6 2,156 2 1 in 539 
12 2,155 3 1 in 718 
 
Table 4: Calculated risks of pGTN in the first 12 months from hCG normalisation for combined CHM 
and UHM 
Months after hCG 
normalisation 
Cases in remission 
 (hCG normal) 
Cases of pGTN  
(total n=26) 
Remaining risk of pGTN 
after this time point 
0 10,558 0 1 in 406 
1 10,553 5 1 in 503 
2 10,549 9 1 in 621 
4 10,548 10 1 in 659 
5 10,547 11 1 in 703 
6 10,546 12 1 in 753 
7 10,545 13 1 in 811 
8 10,544 14 1 in 879 
10 10,543 15 1 in 958 
12 10,540 18 1 in 1,318 
 
Table 5: Cases of HM according to subtype and whether hCG normalises before of after 56 days. 
Subtype Time to hCG normalisation 
Number 
reaching 
normal hCG 
Subsequent 
cases of 
pGTN 
Risk of 
 pGTN  
Odds ratio 
(95% CI) P value 
PHM ≤56 days 4,002 1 1 in 4,002 0.6976 (0.0632-7.696) 0.6227 >56 days 5,584 2 1 in 2,792 
CHM  
(and UHM) 
≤56 days 3,477 3 1 in 1,159 0.265 
(0.0795-
0.8832) 
0.0344 >56 days 7,081 23 1 in 308 
 
